<?xml version="1.0" encoding="UTF-8"?>
<abstract abstract-type="author-highlights" id="ab0015">
 <title>Highlights</title>
 <p>
  <list list-type="simple" id="l0005">
   <list-item id="li0005">
    <label>•</label>
    <p id="p0005">SARS-CoV-2 RdRp shares 97% sequence identity to SARS.</p>
   </list-item>
   <list-item id="li0010">
    <label>•</label>
    <p id="p0010">SARS-CoV-2 RdRp model is built to study different inhibitors.</p>
   </list-item>
   <list-item id="li0015">
    <label>•</label>
    <p id="p0015">Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir can bind tightly the RdRp of SARS-CoV-2.</p>
   </list-item>
   <list-item id="li0020">
    <label>•</label>
    <p id="p0020">Setrobuvir, YAK, and IDX-184 can be used as potent compounds against SARS-CoV-2 RdRp.</p>
   </list-item>
  </list>
 </p>
</abstract>
